Could Tumoroids Solve the Problem of High Attrition in Cancer Trials?

There is growing recognition that the experimental model systems used in many cancer research projects, which include 2D cell cultures, patient-derived xen...

May 01, 2023 | Monday | News
Aquavit Receives FDA Clearance for Two INDs to Initiate Clinical Trials With Its Botulinum Toxin

Aquavit will begin its Phase II/Phase III trials for DTX-023 (aqubotulinumtoxinA) and DTX-024 (aqubotulinumtoxinA with intradermal microinjector) under the...

May 01, 2023 | Monday | News
Janssen Reports First Results of TAR-200 and Cetrelimab Study in Non-Muscle-Invasive Bladder Cancer

Study results of novel drug-eluting technology highlight potential durability of TAR-200 in patient population with high unmet need T...

May 01, 2023 | Monday | News
Tempest Reports Early Results of TPST-1120 Study in First-Line Liver Cancer

Tempest will host a conference call accompanied by a slide presentation at 8:30 a.m. ET on Friday, April 28th. To join the conference call via phone and pa...

April 28, 2023 | Friday | News
Celularity presents clinical data on Cynk-001 in Adult AML patients

In patients with relapsed refractory acute myeloid leukemia (R/R AML) treated with a four-dose regimen consisting of 1.8 billion CYNK-001 cells per dose,...

April 27, 2023 | Thursday | News
Roche's Columvi Gets CHMP Nod for Fixed-Duration Use in Diffuse Large B-cell Lymphoma

The recommendation is based on results from the phase I/II NP30179 study, where Columvi given as a fixed course induced early and long-lasting complete r...

April 27, 2023 | Thursday | Regulatory
Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues

The mice model data indicates considerably shorter half life and accelerated onset while retaining generation-1 MDMA features. The objective of this effort...

April 25, 2023 | Tuesday | News
Sanofi Launches AVAXIM® Junior in UK for Hepatitis A Virus Immunisation in Children

Sanofi (EURONEXT: SAN and NASDAQ: SNY) has today announced the launch of AVAXIM® Junior in the UK, an inactive hepatitis A vaccine indicated for use in...

April 24, 2023 | Monday | News
Belief BioMed Completes Dosing in Registrational Clinical Trial of BBM-H901

BBM-H901 is indicated for prophylactic treatment of bleeding in adults with hemophilia B. It is the first adeno-associated virus (AAV) gene therapy for Hem...

April 24, 2023 | Monday | News
Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applyin...

April 21, 2023 | Friday | News
AbbVie Presents Late-Breaking Atogepant Phase 3 Results for Episodic Migraine Treatment at 2023 AAN Meeting.

The Phase 3 ELEVATE study demonstrated atogepant is effective and well-tolerated for the preventive treatment of episodic migraine in people who previous...

April 21, 2023 | Friday | News
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Announced an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT045...

April 19, 2023 | Wednesday | News
Cali Biosciences Begins Phase III Study of Long-Acting Ropivacaine for Pain Reduction After Surgery

Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali" or "Cali Biosciences"), a biopharmaceutical company focused on the research and development o...

April 19, 2023 | Wednesday | News
HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer

Dr. Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED said, “The NMPA acceptance of our NDA for fruquintinib is a positive step towa...

April 18, 2023 | Tuesday | Regulatory

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close